BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $91.73, for a total transaction of $458,650.00. Following the transaction, the chief executive officer now owns 238,564 shares of the company’s stock, valued at $21,883,475.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Monday, May 8th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $96.09, for a total transaction of $960,900.00.
  • On Thursday, April 27th, Jean Jacques Bienaime sold 5,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $95.72, for a total transaction of $478,600.00.
  • On Tuesday, April 25th, Jean Jacques Bienaime sold 5,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $94.00, for a total transaction of $470,000.00.
  • On Thursday, March 16th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $91.69, for a total transaction of $916,900.00.
  • On Friday, March 10th, Jean Jacques Bienaime sold 11,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.59, for a total transaction of $996,490.00.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded up 0.46% during mid-day trading on Friday, hitting $90.40. 337,278 shares of the company traded hands. The stock’s market capitalization is $15.77 billion. The firm’s 50 day moving average price is $91.09 and its 200-day moving average price is $88.40. BioMarin Pharmaceutical Inc. has a 1-year low of $73.45 and a 1-year high of $102.49.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, May 4th. The biotechnology company reported $0.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.33. BioMarin Pharmaceutical had a negative net margin of 46.22% and a negative return on equity of 8.54%. The company had revenue of $303.70 million for the quarter, compared to analyst estimates of $292.58 million. During the same quarter last year, the firm earned ($0.53) EPS. The firm’s quarterly revenue was up 28.3% compared to the same quarter last year. On average, equities research analysts forecast that BioMarin Pharmaceutical Inc. will post ($0.81) EPS for the current year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

ILLEGAL ACTIVITY NOTICE: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/05/19/jean-jacques-bienaime-sells-5000-shares-of-biomarin-pharmaceutical-inc-bmrn-stock.html.

Several institutional investors have recently added to or reduced their stakes in the stock. Parallel Advisors LLC raised its position in BioMarin Pharmaceutical by 13.6% in the first quarter. Parallel Advisors LLC now owns 1,042 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 125 shares in the last quarter. Nikko Asset Management Americas Inc. acquired a new position in BioMarin Pharmaceutical during the first quarter valued at approximately $114,000. Global X Management Co. LLC raised its position in BioMarin Pharmaceutical by 59.7% in the first quarter. Global X Management Co. LLC now owns 1,656 shares of the biotechnology company’s stock valued at $145,000 after buying an additional 619 shares in the last quarter. Toronto Dominion Bank raised its position in BioMarin Pharmaceutical by 27.1% in the first quarter. Toronto Dominion Bank now owns 1,881 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 401 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its position in BioMarin Pharmaceutical by 20.0% in the first quarter. Mutual of America Capital Management LLC now owns 2,066 shares of the biotechnology company’s stock valued at $181,000 after buying an additional 344 shares in the last quarter. 97.78% of the stock is currently owned by institutional investors.

Several brokerages have commented on BMRN. JPMorgan Chase & Co. set a $123.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Saturday, February 25th. Cowen and Company restated a “buy” rating and set a $150.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday. Jefferies Group LLC restated a “buy” rating and set a $116.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday. Wedbush restated a “hold” rating and set a $108.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, May 8th. Finally, Deutsche Bank AG set a $105.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Friday, April 28th. Eight analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $111.77.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

5 Day Chart for NASDAQ:BMRN

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.